Royal Bank of Canada’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Royal Bank of Canada’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-131	Closed	-$3K	–	7973
2023 Q2	$3K	Buy	+131	New	+$951	﹤0.01%	6825
2022 Q4	–	Sell	-1,400	Closed	-$9K	–	8035
2022 Q3	$9K	Buy	1,400 +15	+1%	+$137	﹤0.01%	6504
2022 Q2	$15K	Sell	1,385 -125	-8%	-$1.68K	﹤0.01%	6231
2022 Q1	$28K	Sell	1,510 -147	-9%	-$3.28K	﹤0.01%	6434
2021 Q4	$60K	Buy	1,657 +1,497	+936%	+$85.2K	﹤0.01%	6266
2021 Q3	$12K	Buy	160 +107	+202%	+$8.23K	﹤0.01%	6918
2021 Q2	$7K	Sell	53 -41	-44%	-$7.2K	﹤0.01%	7004
2021 Q1	$27K	Buy	+94	New	+$37.4K	﹤0.01%	6268

Other funds holding SGTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Royal Bank of Canada's SGTX Position: Q3 2023 in Review

Royal Bank of Canada sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2023, closing a stake of 131 shares — an estimated $3K sold.

Royal Bank of Canada first reported a position in SGTX in Q1 2021 and held it in 8 quarters. The position peaked at $60K in Q4 2021. 1 fund tracked by Wall St. Rank holds SGTX as of Q3 2023.

Royal Bank of Canada reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Royal Bank of Canada sold 131 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3K.
Royal Bank of Canada first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Royal Bank of Canada's Sigilon Therapeutics, Inc. Common Stock position peaked at $60K in Q4 2021.
1 fund tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Royal Bank of Canada's 13F filing for Q3 2023, filed 14 Nov 2023.